Management's discussion and analysis (MD&A) is current to March 31, 2017 and is management's assessment of the operations and the financial results together with future prospects of Nutritional High International Inc. ("Nutritional High", or the "Company"). This MD&A should be read in conjunction with the Company’s unaudited condensed interim consolidated financial statements and related notes for the six months ended January 31, 2017, prepared in accordance with International Financial Reporting Standards ("IFRS"). All figures are in Canadian dollars unless stated otherwise.

This discussion contains forward-looking statements that are historical in nature and involves risks and uncertainties. Forward-looking statements are not guarantees as to Nutritional High’s future results as there are inherent difficulties in predicting future results. This MD&A includes, but is not limited to, forward looking statements. Management considers the assumptions on which these forward-looking statements are based to be reasonable at the time the statements were prepared. Accordingly, actual results could differ materially from those expressed or implied in the forward-looking statements.
Nutritional High International Inc. ("Nutritional High" or "the Company" or "NHII"), formerly Sonoma Capital Inc., is a publicly traded company incorporated in Canada on July 19, 2004 under the Canada Business Corporations Act. The Company's objective is to take advantage of the changing regulation governing the marijuana industry in the United States and Canada. The address of the Company's registered office is 77 King Street West, Suite 2905, Toronto, Ontario M5K 1H1. The Company is listed on the Canadian Securities Exchange (CSE) under symbol "EAT". The Company is also listed on the OTCQB Marketplace under US symbol: "SPLIF", and the Frankfurt Stock Exchange under the symbol: "2NU".

The table below lists the Company’s subsidiaries and investments in affiliates and ownership interests in each.

<table>
<thead>
<tr>
<th>Subsidiary/Affiliate</th>
<th>% ownership</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>31-Jan-17</td>
</tr>
<tr>
<td>NHII Holdings Ltd. (&quot;NHHL&quot;), formerly Nutritional High Ltd.</td>
<td>100%</td>
</tr>
<tr>
<td>NHC IP Holdings Corp. (&quot;NHCIP&quot;), formerly NH Real Estate Holdings Ltd.**</td>
<td>100%</td>
</tr>
<tr>
<td>Nutritional High (Colorado) Inc. (&quot;NHCI&quot;)</td>
<td>100%</td>
</tr>
<tr>
<td>NH Properties Inc. (&quot;NHPI&quot;)</td>
<td>100%</td>
</tr>
<tr>
<td>NH Medicinals (Maryland) Inc. (&quot;NHMMI&quot;) *</td>
<td>-</td>
</tr>
<tr>
<td>NHC Edibles LLC (&quot;NHC&quot;)</td>
<td>100%</td>
</tr>
<tr>
<td>NH Medicinal (Minnesota) Inc. (&quot;NHMM&quot;)</td>
<td>100%</td>
</tr>
<tr>
<td>Nutritional IP Holdings LLC (&quot;NIPH&quot;)</td>
<td>100%</td>
</tr>
<tr>
<td>Nutritional High (Oregon) LLC (&quot;NHOL&quot;)</td>
<td>100%</td>
</tr>
<tr>
<td>Nutritional Traditions Inc. (&quot;NTI&quot;)</td>
<td>100%</td>
</tr>
<tr>
<td>Eglinton Medicinal Advisory Ltd. (&quot;EMAL&quot;)</td>
<td>51%</td>
</tr>
<tr>
<td>NH Medical Dispensaries LLC (&quot;NHMD&quot;)</td>
<td>50%</td>
</tr>
<tr>
<td>Small’s Mill Holdings Inc. (&quot;SMHI&quot;)</td>
<td>50%</td>
</tr>
<tr>
<td>Aura Health Corp. (&quot;AHC&quot;)</td>
<td>24%</td>
</tr>
</tbody>
</table>

* NHMMI was dissolved in October 2016.
** Name changed effective March 15, 2017.
The Company's business is focused on the production of marijuana oils, extracts and edibles (the “Marijuana-Infused Products Segment”) and it is developing a business plan relating to hemp-infused products (the “Hemp-Infused Products Segment”). In its Marijuana-Infused Products Segment, the Company is focused on developing, acquiring and designing marijuana-infused products and marijuana concentrate products and brands for sale by the Company where it has secured the required licensing, or for use by licensed operators (“Licensed Operators”) entering into royalty or packaging agreements with the Company in jurisdictions where permitted. In its Hemp-Infused Products Segment, the Company intends on developing brands, trademarks, products and packaging for products infused with hemp extract that have less than 0.3% tetrahydrocannabinol (“THC”) and are not subject to the same regulation as the products in the Company's Marijuana-Infused Products Segment. Through NHMD, Nutritional High is retailing marijuana products to medical marijuana patients in the State of Illinois. With respect to its Colorado project, Nutritional High has recognized accrued rent, earned interest and consulting income and is in the process of entering into royalty or packaging agreement with Palo Verde LLC, which has recently commenced production of cannabis bulk oil. As such, the Company is considered to be a development stage entity.

On March 13, 2015, the Company completed its initial public offering of units, which raised gross proceeds of $1,645,000 through its agent Jacob Securities Inc. Each unit comprised of one Common Share and one-half of one common share purchase warrant. Each whole common share purchase warrant entitles the holder thereof to purchase a Common Share at a price of $0.07 per share until March 13, 2017. The Company's Common Shares commenced trading on the Canadian Securities Exchange at the opening of market on March 23, 2015, under the trading symbol “NHL”. On August 24, 2015, the Company changed its trading symbol on the CSE to "EAT".

As at March 31, 2017, the members of Company's management and Board of Directors consisted of:

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jim Frazier</td>
<td>Chief Executive Officer</td>
</tr>
<tr>
<td>Amy Stephenson</td>
<td>Chief Financial Officer</td>
</tr>
<tr>
<td>Adam Szweras</td>
<td>Secretary and Director</td>
</tr>
<tr>
<td>David Posner</td>
<td>Chairman of the Board</td>
</tr>
<tr>
<td>David Caplan</td>
<td>Director</td>
</tr>
<tr>
<td>Brian Presement</td>
<td>Director</td>
</tr>
<tr>
<td>Billy Morrison</td>
<td>Director, Executive VP, Extraction of NHC</td>
</tr>
<tr>
<td>Robert Keeler</td>
<td>Director</td>
</tr>
</tbody>
</table>

The Company has also formed an advisory board (the "Advisory Board") to provide expertise and advice to the senior management team regarding operational matters relating to the execution of the Company's business plan. The Advisory Board is comprised of Frank Galati and Debra Zwiefelhofer.

**Business Overview**

The Company operates in the medical marijuana, adult use marijuana and hemp infused products sectors in the United States, and other jurisdictions where such activity is permitted and regulated by applicable laws, through entities that hold a valid license to produce and distribute such products in accordance with applicable regulations.

The Company has two distinct objectives as a part of the separate business units:
Marijuana-Infused Products Segment. In its Marijuana-Infused Products Segment, the Company is focused on developing, acquiring and designing marijuana-infused products and marijuana concentrate products and brands for sale by the Company where it has secured the required licensing, or for use by Licensed Operators entering into royalty or packaging agreements with the Company in jurisdictions where permitted; and

Hemp-Infused Products Segment. The Company is further developing a business plan to acquire, manufacture and distribute products infused with non-psychoactive constituent of the industrial hemp plant (less than 0.3% THC or otherwise as permitted by applicable law), which may be distributed in all 50 states. The Company intends on pursuing a retail distribution strategy through networks of retail dispensaries where THC products are sold, head shops, vitamin stores and independent grocers via direct sales and distributors and is considering online sales, and multi-level marketing.

The Company will establish operations only in U.S. States ("States") which have implemented or are implementing adequate licensing frameworks to comply with the "Cole Memo" (as hereinafter described below).

Marijuana-Infused Products Segment

In its Marijuana-Infused Products Segment, the Company is focused on developing, acquiring and designing marijuana-infused products and marijuana concentrate products and brands for use by Licensed Operators. The Company enters into raw materials, packaging agreements or royalty agreements with Licensed Operators with respect to the Company's brands, recipes and know-how. The Company also sells packaging material to Licensed Operators with the Company's branding as permitted by the applicable regulation.

In the State of Colorado, licensed cannabis businesses are subject to residency requirements, which preclude Nutritional High and its subsidiaries from having an interest in any proceeds from production, processing, or retailing activities. Nutritional High has a lease agreement and loan agreements with Palo Verde LLC ("Palo Verde"), a Licensed Operator in Colorado, and is negotiating other commercial agreements with Palo Verde, including royalty and packaging agreements. The Company earns rent, interest, and consulting income from Palo Verde, which has recently commenced production of cannabis bulk oil. Accordingly, Nutritional High is a landlord, lender and consultant, and a licensor of its FLI brand in Colorado and ensures that all products under the FLI and Nutritional High brand meet or exceed the Company’s brand quality and standards.

In the State of Illinois, Nutritional High is retailing marijuana products to medical marijuana patients through NHMD operating as The Clinic Effingham ("TCE") in Effingham, Illinois. NHMD is a 50-50 joint-venture with an Illinois investor group ("ILDISP") with experience in marijuana products. ILDISP is the operator of TCE and will receive a fee equal to 100% of TCE’s net profit. Nutritional High has also entered into agreement with an Illinois cannabis cultivation and extraction facility to develop a framework under which the extraction facility will manufacture and distribute our oils and edibles in Illinois. The agreement provides the Company the right to negotiate a framework in good faith.

The Marijuana-Infused Products Segment is solely focused on States where marijuana-infused products are permitted by law and regulations.

Hemp-Infused Products Segment

In its Hemp-Infused Products Segment, the Company intents to develop, acquire, manufacture and distribute products infused with non-psychoactive constituents of the industrial hemp plant (less than 0.3% THC or as otherwise permitted by applicable law), which may be distributed in all 50 states. The Company will pursue a distribution strategy through: (i) networks of retail dispensaries, such as head shops, vitamin stores; and (ii) independent grocers, via direct sales and distributors, where THC products are sold. The Company is also considering online sales, and multi-level marketing. The Company’s product, including hemp-infused hard candies, chews, gummies and other items, are expected to have competitive edge in the market as a result of the Company’s expertise in manufacturing products from cannabis.
Cole Memo Compliance

In a memorandum dated August 29, 2013, addressed to "All United States Attorneys" from James M. Cole, Deputy Attorney General (the "Cole Memo"), the U.S. Department of Justice acknowledged that certain States had enacted laws relating to the use of marijuana and outlined the U.S. federal government's enforcement priorities with respect to marijuana notwithstanding the fact that certain States have legalized or decriminalized the use, sale and manufacture of marijuana:

- Preventing the distribution of marijuana to minors;
- Preventing revenue from the sale of marijuana from going to criminal enterprises, gangs, and cartels;
- Preventing the diversion of marijuana from States where it is legal under state law in some form to other States;
- Preventing U.S. State-authorized marijuana activity from being used as a cover or pretext for the trafficking of other illegal drugs or other illegal activity;
- Preventing violence and the use of firearms in the cultivation and distribution of marijuana;
- Preventing drugged driving and the exacerbation of other adverse public health consequences associated with marijuana use;
- Preventing the growing of marijuana on public lands and the attendant public safety and environmental dangers posed by marijuana production on public lands; and
- Preventing marijuana possession or use on U.S. federal property.

There is no guarantee that the current presidential administration will not change the stated policy of the previous administration regarding the low-priority enforcement of U.S. federal laws that conflict with state laws. The incoming Trump administration and the newly elected Congress could decide to enforce U.S. federal laws vigorously.

The Company’s operations are compliant with the Cole Memo.

Compliance and business model

The Company's business model in its Marijuana-Infused Products Segment differs in each state depending on the residency requirements of the state. Most states that have legalized marijuana for medical or recreational use require the business or individual to hold valid license(s), under state regulations. Some states require the license holder and/or owner of the Licensed Operator to be a state resident. As such, listed companies or other widely held enterprises are ineligible to obtain a license in those states. In such states, the Company will work with a Licensed Operator by providing them with financing, products, recipes, brands, know how, consulting services and may purchase the facilities where such License Operators operate or intend to operate. In states where there are no residency requirements and where the Company can acquire licensing on its own, the Company may apply to become a License Operator. The Company will not operate in jurisdictions which have not legalized marijuana, or have not developed a licensing regime for Licensed Operators.

In states with residency requirements, the Company may conduct business in the value chain segments, which do not require a license. Such ancillary value chain segments do not directly handle, process, manufacture, cultivate or distribute cannabis products, and may include: (i) secured and unsecured lending; (ii) providing real estate to Licensed Operators; (iii) equipment leasing; and (iv) providing non-cannabis raw materials, such as packaging and food ingredients, etc. The focus of this strategy is to provide a competitive advantage to selected Licensed Operators that specialize in extraction and processing of cannabis, for an above average economic return to the Company.

In certain circumstances the Company may pursue other value chain segments, such as operating a dispensary, in the states where the regulatory environment is unsuitable to earn an economic rate of return in the extraction/processing segment, given the Company's assessment. The purpose of this strategy is to secure a foothold in such markets, through obtaining a license to operate a business that is not directly related to extraction/processing and then partner with another licensed operator who can operate in the extraction/processing space. The Company has employed this type of strategy in the State of Illinois, where it is has obtained a dispensary license, and plans to partner with a Licensed Operator to manufacture and sell its products in Illinois.
Business Developments

State of Illinois Developments

The Company entered into a joint-venture agreement ("JV Agreement") with an Illinois investor group ("ILDISP") with ties to the medical marijuana industry to build and operate the Company’s Dispensary in Effingham, Illinois, with the intention of the investor group acquiring a 50% interest in NHMD, the Company’s wholly owned subsidiary, which owns and operates the Dispensary, and a 50% interest in SMHI, the Company’s wholly owned subsidiary which holds the Company’s real estate property in Lawrenceville, IL. Under the terms of the JV Agreement the Illinois investor group funded USD $300,000 of the expenses and working capital required to complete and launch the Dispensary. In addition, this investor group provided the Company with a guarantee for half the Seller Take-Back Mortgage over the Company’s property in Lawrenceville, IL, initially intended to be used for the Dispensary.

On September 17 2016, the Illinois investor group funded USD $300,000 of the expenses and working capital required to complete and launch the Dispensary under joint-venture agreement. Accordingly, as of September 2016, the investor group and NHII each has a 50% equitable interest in NHMD, and 50% equitable interest in SMHI. The NHMD clinic has been operating as The Clinic Effingham ("TCE") since September 17, 2016.

The Company had previously intended to locate its Dispensary in Lawrenceville. In June 2016, based on the advice from ILDISP, the Company agreed to relocate to Effingham, Illinois. Effingham County is located in the middle of ISP District 12 and has approximately twice the population of Lawrenceville County. The Effingham location provides significant additional patient access and is situated next to a Veteran's Affairs Clinic. Its location is in the heart of central Illinois and is adjacent to the intersection of two major interstate highways: I-57 and I-70. Located approximately 50 miles North West of the originally intended location in Lawrenceville, IL, the new location is within minutes of the Keller Drive exit and entrance ramps which provides full on-off interstate access in all directions. The Effingham location is a high traffic regional business and retail district with several major big box retailers within minutes. It is adjacent to a Veteran’s Affairs Clinic which provides convenient access for an important patient group. The Company has since sold the Lawrenceville property back to its original vendors (see subsequent events).

On September 20, 2016, the Company began operating its medical cannabis dispensary in Effingham, IL through NHMD, which has received a medical cannabis dispensary license under the Compassionate Use of Medical Cannabis Pilot Program Act (Illinois) ("CUMCPPA") in August 2016. Immediately following the receipt of its Approval, the Clinic Effingham held a successful open house with over 100 attendees including local government and law enforcement officers.

The Company has also entered into agreement with an Illinois cannabis cultivation and extraction facility to develop a framework to manufacture and distribute Nutritional High’s oils and edibles. The cultivation and extraction facility is licensed with Illinois Department of Agriculture and was amongst the first of the companies to commence commercial cultivation and processing of cannabis products under the CUMCPPA. This project is part of the Company’s longer term expansion plan.

Colorado Project Update

The Company has assisted Palo Verde LLC ("Palo Verde"), its Colorado and Licensed Operator tenant, in commencing operations in Colorado. The initial build-out of the Company’s facility in West Pueblo, CO, which is leased to Palo Verde, has been completed and Palo Verde has commenced the production of solid and liquid cannabis concentrates and vape pen cartridges. The Company is planning the next phase of build-out which will allow Palo Verde to manufacture various marijuana-infused products such as gel capsules and varies edibles.

Palo Verde has hired key personnel including a general manager/oils and extraction specialist. Palo Verde’s extraction equipment allows Palo Verde to use an extraction process that utilizes a combination of mechanical separation and short-path distillation to extract essential oils from raw cannabis into high purity product, dubbed as “Clear” in the industry.
Palo Verde has commenced start with the sale of raw oil to other infused product manufacturers, prior to launching the sale of cannabis-infused products such as gelatine caps, vape pen cartridges and disposable vape pens. Concurrent with product introduction, the Company is assisting Palo Verde to commence the manufacture of cannabis infused edible products.

On February 22, 2017, the Company provided an update the Colorado project. Palo Verde is aggressively accelerating bulk oil extraction and sales. With the help of Nutritional High’s personnel, Palo Verde has successfully streamlined its processes to maximize oil extraction yield and developed methods to increase throughput capacity. In this regard, the Company has purchased a state of art distillation plant, manufactured in Germany, which will be leased to Palo Verde and has been delivered to the Pueblo facility. The plant combines a wiped film evaporator and condenser in a single apparatus and can process up to 1.5L of oil per hour into distillate. The Company has purchased additional equipment, and once installation is complete, Palo Verde’s capacity is expected to increase significantly, driving additional revenue.

California Expansion Strategy

On November 1, 2016, the company announced its expansion strategy in the State of California in anticipation of the introduction of the Adult Use of Marijuana Act on November 8, 2016. As an initial step of the California expansion strategy, the Company purchased and took delivery of equipment to facilitate cold ethanol extraction. The equipment would be stored in a warehouse in California pending installation once an appropriate facility is secured.

Acquisition of interest of Aura Heath Corp.

On November 17, 2016, the company acquired a 40% equity interest in Aura Health Corp. ("AHC"), a private company based in Ontario, which owns and operates Green Global Properties Inc., a private company incorporated in Delaware (the “Green Global”). The Company also advanced to AHC a convertible debenture in the principal amount of US$120,000 (the "Principal Amount"), bearing 12% interest per annum. The Principal Amount and all accrued interest are due and payable in two years. AHC is involved in the development and acquisition of medical marijuana health clinics in the United States. The medical health clinics test prospective patients, and where applicable and where it is legal to do so, issues medical-use certificates to qualifying patients in the United States. AHC, through Green Global, completed its first acquisition of a 30% ownership interest in a recently opened clinic in Las Vegas, Nevada from Sun Valley Holdings ("Sun Valley"), a private company based in Phoenix, Arizona. Sun Valley currently operates three wholly owned clinics in Arizona and is the largest clinic owner and operator in the state of Arizona.

On December 28, 2016, the Company announced that AHC has made a 50% deposit to acquire a 30% investment interest in a second clinic, to be opened in a busy retail district in Mesa, Arizona. The clinic will be operated by Sun Valley. AHC has an option to acquire up to 51% ownership of the clinic within 18 months of the initial investment. The Company also announced that AHC has closed a unit private placement, consisting of 6,550,000 units at a price of $0.10 per unit for aggregate gross proceeds of $655,000, reducing the Company’s ownership to approximately 24%.

The Company expects AHC to be an important partner in distribution of Nutritional High product in various key medical marijuana markets including Nevada and Florida, where additional clinics are planned. This relationship with AHC will provide the Company exposure to medical marijuana patients which will be an important component of the Company’s product distribution channel.

Launch of an innovative “Dab Stick” product

On January 30, 2017, the Company announced that it has entered into agreement to acquire the technology and intellectual property rights of the “Dab Stick”. The Dab Stick is an innovative dispenser for viscous liquid substances, capable of carrying approximately ½ gram of cannabis oil extract designed with the retail consumer and adult use user in mind. The oil vessel is capable of dispensing oil in very small metered doses, which ensures consistency between each dose of oil dispensed and providing desired consumer experience. While there have been similar products introduced in the California market (and have subsequently discontinued), Dab Stick uses a revolutionary patent pending process which solves technical failings of such past discontinued products.
A provisional patent application has been filed with the United States Patent and Trademark Office (the "USPTO") for the Dab Stick and the vendors of the technology has completed a conceptual design and prototype of the Dab Stick. Together with the Vendor, Nutritional High is currently in the process of locating a suitable manufacturer to supply the product to Nutritional High’s facilities in the United States.

**Acquisition of cultivation and production licenses in Henderson, Nevada**

The Company is in the process of acquiring provisional and production licenses in Henderson, Nevada and a real estate property to which the Licenses are attached. As consideration for the acquisition, the Company has paid an escrow agent US$1,000,000 for the License and a deposit of US$160,000 for the property.

**Key Board and Management Changes**

During the six months ended January 31, 2017 and year ended July 31, 2016, the Company has made the following management changes:

On April 27, 2016, the Company appointed Jim Frazier as Chief Operating Officer of the Company. Jim Frazier has over 23 years of experience in the food industry and a proven track record of developing and implementing branded and private label programs and driving profits. He is also a well-known manufacturer of confections, with 40 years of experience.

On June 14, 2016, the Company appointed Amy Stephenson as Chief Financial Officer. Amy Stephenson has over 20 years of senior management and capital markets experience. She was former CFO of Bedrocan Cannabis Corp. and controller of Canopy Growth Inc. She has a strong familiarity with the cannabis and hemp industries.

On June 16, 2016, the Company appointed Robert Keeler as the Company’s new independent director. Mr. Keeler has over 20 years of experience in the food manufacturing industry and specializes in USDA Food Production, HACCP Certified and GMP. He is currently the Chief Operating Officer of Dude, Sweet Chocolate, which is a vertically integrated manufacturer, wholesaler and retailer of unique, world-class dark chocolate creations.

On July 25, 2016, Jim Frazier replaced David Posner as the Company’s Chief Executive Officer. David Posner has been appointed as Chairman of the Board, replacing Statis Rizas, who resigned as a chairman and director of the Company.

**Frankfurt Stock Exchange Listing and German Strategy Announcement**

On May 24, 2016, the Company announced that its common shares commence trading on the Frankfurt Stock Exchange under the symbol "2NU". The Frankfurt Stock Exchange is the world’s 10th largest stock exchange by market capitalization and the largest of Germany’s seven stock exchanges.

On July 14, 2016, the Company announced its strategy regarding international expansion. Nutritional High's mandate is to capitalize on regulatory changes in jurisdictions where cannabis and cannabis derivative products are permitted by the requisite government authorities for medical or adult use. The Company continues to monitor the legislative environment in jurisdictions where a significant market potential exists. Nutritional High has identified Germany as being one of the markets where the regulatory change is currently underway.

**Launch of Jimi Hendrix Related Cannabis Products**

On August 31, 2016, the Company and Purple Haze Properties LLC ("PHP") announced the launch of Jimi Hendrix related cannabis-infused products, and the entry into an addendum to their license agreement to provide for sub-licensing to third parties in Oregon and California.

To facilitate these sub-licensing arrangements, Nutritional High and PHP have entered into amending agreement to their June 5, 2015 license agreement where Nutritional High acquired the exclusive rights to manufacture and distribute Gummy Bears, Hard Candies and Vitamin Water style beverages for Jimi’s Cannabis Collection. Nutritional
NUTRITIONAL HIGH INTERNATIONAL INC.
Management's Discussion and Analysis
of Financial Condition and Results of Operations
For the six months ended January 31, 2017

High can terminate these sublicensing arrangements when it decides to launch its own product offerings in those states.

Changes in Investor Relations Services Providers

On September 1, 2016, the Company announced the engagement of Boom Capital Markets ("Boom Capital") to provide investor relations services. Boom Capital is an investor relations specialist in the micro-cap sector, focuses on introducing Canadian companies of merit to broader institutional and retail investors.

On February 27, 2017, the Company announced that it has engaged 360 Aviation Services Inc. ("360") to provide investor relations services pursuant to an investor relations consulting agreement dated February 16th, 2017. The consulting agreement has an initial 3-month term and is renewable at the mutual agreement of both parties. 360 will be paid a monthly fee of $5,000 with stock options to acquire up to 500,000 Common Shares at an exercise price of $0.20 per share for 2 years, subject to vesting provisions of 25% every three months in accordance with the policies of the regulatory authorities and NHII’s Stock Option Plan.

Launching Flagship “FLI” Brand

On December 19, 2016, the Company announced that it has completed brand development and is commencing the launch of its flagship line of products under the brand name “FLI”. Nutritional High is finalizing the formulations for each of the products, for manufacture by Palo Verde at the Company’s Pueblo facility. In addition to the launch of its liquid concentrates for bulk sale and in cartridges the company expects to introduce additional product lines: Various additional consumer-focused Concentrate Products; and Cannabis-Infused Edible Products.

Other marijuana-infused products being introduced are FLI-branded disposable vape pens and gelatin capsules, which can be manufactured using the current infrastructure at the Pueblo facility. The team has began formulating innovative edible products that will be manufactured at the Pueblo facility once the chocolate enrobing equipment has been installed and properly calibrated. Consistent with Nutritional High’s vision, the team will focus on semi-automated manufacturing of the edibles in order to meet market demand once the products are introduced for commercial sale. The edible products are expected to be introduced in the Spring of 2017.

The Company’s branding consultant is also assisting in the development of packaging for an initial line of Jimi Hendrix-branded products.

Key Financing Developments

On August 26, 2016, the Company closed the first tranche of non-brokered private placement, consisting of 11,432,580 Units for aggregate gross proceeds of $400,140. The proceeds from the offering will be used by the Company to fund the Company's Pueblo project, service debt and for general working capital purposes. In connection with the first tranche of this private placement, the Company paid transaction cost of $5,460 and issued 22,857 finder’s units. Each finder’s unit is exercisable at $0.035 for 18 months from closing and each finder’s unit comprised of one common share and one half of a warrant with an exercise price of $0.05 expiring 18 months from closing.

On September 9, 2016, the Company closed the second tranche of non-brokered private placement, consisting of 11,445,960 Units at a price of $0.035 per Unit for aggregate gross proceeds of $400,609. The total number of Units issued pursuant to this Offering, together with the first tranche as announced on August 31, 2016, is 22,878,540 for aggregate gross proceeds of $801,749. In connection with the second tranche of this private placement, the Company incurred $12,591 of transaction and commission costs and issued 133,143 finder’s warrants. Each warrant is exercisable at $0.035 for 18 months after closing.

On September 12, 2016, the Company issued 8,870,844 units to settle $443,542 of debt at a deemed price of $0.05 per unit. Each unit is comprised of one common share and one half common share purchase warrant. Each warrant entitles the holder to purchase one common share at price of $0.07 per common Share for a period of 18 months after
the closing date. A total of 6,665,174 units were issued to non-arm’ length parties to settle the debts in the amount of $333,258. A gain of $132,657 is recognized as a result of this debt settlement.

On October 6, 2016, subordinate convertible debenture of $150,000 together with interest owing of $26,090 were converted to 2,934,830 common shares at the price of $0.06 per share.

On October 14, 2016, the Company granted 170,000 stock options to Soar Financial Partners, a provider of Investor Relations and Public Relations services to purchase common shares of the Company at the exercise price of $0.13 exercisable from time to time up to October 14, 2018.

On October 17, 2016, the Company granted 500,000 stock options to Boom Capital Partners Inc., a provider of Investor Relations and Public Relations services, and 2,450,000 stock options to the Company’s Directors, officers, and Consultant to purchase common shares of the Company at the exercise price of $0.135 exercisable from time to time for a period of five years from the date of issuance.

On November 8, 2016, the company completed the first tranche of a non-brokered private placement, consisting of 7,658,710 units at a price of $0.15 per Unit to raise aggregate gross proceeds of $1,148,807. Each Unit consists of one common share of the Company and one-half of one Common Share purchase warrant. Each Warrant entitles the holder to purchase a Common Share at $0.22 per share for a period of 18 months from closing. The Company incurred $113,996 of transaction and commission costs and issued 552,884 finder’s units. Each finder’s unit is exercisable at $0.15 for 24 months and each finder’s unit comprised of one common share and one half of a warrant with an exercise price of $0.22 expiring 24 months from closing.

On November 8, 2016, the Company closed the second tranche of the non-brokered private placement, consisting of 25,615,880 units at a price of $0.15 per unit for an aggregate gross proceeds of $3,842,382. Each unit consists of one common share of the Company and one-half one common share purchase warrant. Each Warrant entitles the holder to purchase a Common Share at $0.22 per share for a period of 18 months from closing. In connection with the private placement, the Company incurred $379,277 of transaction and commission costs and issued 1,933,462 finder’s units. Each finder’s unit is exercisable at $0.15 for 24 months and each finder’s unit comprised of one common share and one half of a warrant with an exercise price of $0.22 expiring 24 months from closing.

On November 24, 2016, the Company closed the final tranche of the non-brokered private placement, consisting of 3,194,965 units at a price of $0.15 per Unit to raise aggregate gross proceeds of $479,245. Each unit consists of one common share of the Company and one-half one common share purchase warrant. Each Warrant entitles the holder to purchase a Common Share at $0.22 per share for a period of 18 months from closing. In connection with the private placement, the Company incurred $51,555 of transaction and commission costs and issued 285,270 finder’s units. Each finder’s unit is exercisable at $0.15 for 24 months and each finder’s unit comprised of one common share and one half of a warrant with an exercise price of $0.22 expiring 24 months from closing.

On November 29, 2016, the Company granted 315,000 stock options to four arm’s length consultants. The options are exercisable into Common Share of the Company at a price of $0.30 per Common Share for a period of two years from the date of issuance.

**Overall Performance**

As at January 31, 2017, the Company had assets of $9,726,002 (2016 – $2,686,449), liabilities of $1,179,752 (2016 - $2,310,944) and shareholders' equity of $8,546,250 (2016 – $375,505). During the six months ended January 31, 2017, the Company incurred a net income and comprehensive loss of $642,150 (2016 – loss of $661,522).

As at January 31, 2017, the Company had working capital of $4,955,754 (2015 – working capital deficiency of $1,432,542) and cash of $5,840,865 (2015 – $111,786).

**Selected Annual Information**

Summarized selected financial information with respect to Nutritional High is as follows:
Operating results for three months ended January 31, 2017

For the three months ended January 31, 2017, the Company incurred a net loss of $716,224 or $0.003 per Common Share compared with a net loss of $300,174 or $0.002 per Common Share for the same period ended January 31, 2016. This is primarily due to: (i) change in fair value of derivative liability of $(202,995) (2016 – $81,902), a difference of $284,897, as a result of the impact of the increase in share price; (ii) increase in finance costs of $74,315 to $284,897; (iii) loss from investment of $65,036 (2016 - $Nil). This is off set by a gain on debt settlement of $132,657 (2016 - $Nil).

For the three months ended January 31, 2017, operating expenses were $617,732 (2016 - $507,014) due to considerable increase in operating activities after the Company completed financings totalling gross proceeds $5,470,434 and immediately geared up operating and other activities including: (i) the acquisition of the Dab Stick; (ii) investment in AHC; (iii) expansion in California.

For the three months ended January 31, 2017, profession fees, consisting of legal and audit fees, increased by $9,819 to $61,727 (2016 - $51,908) despite active financing, acquisition and investment activities during the quarter.

The Company earned $129,907 in rental income on the Pueblo location for the three months ended January 31, 2017, and $133,856 for the comparable period in the prior year.

Operating results for six months ended January 31, 2017

For the six months ended January 31, 2017, the Company incurred a net loss of $642,150 or $0.003 per Common Share compared with a net loss of $661,675 or $0.005 per Common Share for the same period ended January 31, 2016. This is primarily due to a one time gain of $824,390 (2016 - $Nil) on the deconsolidation of NUTRITIONAL HIGH INTERNATIONAL INC. and SMHI (Notes 16 and 20 of the condensed interim financial statement for the six months ended January 31, 2017) and a gain on debt settlement of $132,657 (2016 - $Nil) off set by operating loss of $1,221,040 (2016 – $589,138).

For the six months ended January 31, 2017, all operating expenses are higher than the same period last year, reflecting the increased in activities of the Company, except for management and consulting fees which decreased by $132,479 to $416,545 from $549,024 in the same period in 2016, consisting of strategic advisory services provided by FMI Capital Advisory Inc., and financial accounting services, including CFO services Branson Corporate Services Ltd. and services provided by the President and CEO of the Company. The reduction in management and consulting fees is primarily due to the replacement of a number of consultants and by a new CEO of the Company, a cost savings to the Company in excess of $173,000.
For the six months ended January 31, 2017, professional fees, consisting of legal and audit fees, increased by $68,531 to $145,156 from $76,625 for the comparable period in the prior year due to increase in operating and financing activities.

The Company earned $257,790 in rental income on the Pueblo location for the six months ended January 31, 2017, and $259,543 for the comparable period in the prior year.

Selected financial information for the previous quarters as follows:

<table>
<thead>
<tr>
<th>Quarter ended</th>
<th>Revenues</th>
<th>Net loss and comprehensive loss</th>
<th>Net loss per share</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 31, 2017</td>
<td>$nil</td>
<td>$(716,224)</td>
<td>$(0.003)</td>
</tr>
<tr>
<td>October 31, 2016</td>
<td>$nil</td>
<td>$74,074</td>
<td>$0.0005</td>
</tr>
<tr>
<td>July 31, 2016</td>
<td>$nil</td>
<td>$(1,057,167)</td>
<td>$(0.008)</td>
</tr>
<tr>
<td>April 30, 2016</td>
<td>$nil</td>
<td>$(584,995)</td>
<td>$(0.004)</td>
</tr>
<tr>
<td>January 31, 2016</td>
<td>$nil</td>
<td>$(300,174)</td>
<td>$(0.002)</td>
</tr>
<tr>
<td>October 31, 2015</td>
<td>$nil</td>
<td>$(361,348)</td>
<td>$(0.003)</td>
</tr>
<tr>
<td>July 31, 2015</td>
<td>$nil</td>
<td>$(699,055)</td>
<td>$(0.006)</td>
</tr>
<tr>
<td>April 30, 2015</td>
<td>$nil</td>
<td>$(631,933)</td>
<td>$(0.005)</td>
</tr>
</tbody>
</table>

Liquidity and Financial Position

Liquidity risk is the risk that the Company will not have sufficient cash resources to meet its financial obligations as they come due. The Company's liquidity and operating results may be adversely affected if the Company's access to the capital market is hindered, whether as a result of a downturn in stock market conditions generally or related to matters specific to the Company. The Company generates cash flow primarily from its financing activities. The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at January 31, 2017, the Company had current assets of $6,135,506, current liabilities of $1,179,752 and working capital of $4,955,754.

The following are the contractual maturities of financial liabilities as at January 31, 2017:

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Less Than 1 Year</th>
<th>1 to 2 Years</th>
<th>Greater than 2 Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable, accrued liabilities</td>
<td>$167,168</td>
<td>$167,168</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Promissory note payable</td>
<td>$1,012,584</td>
<td>$1,012,584</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
Related Party Transactions and Key Management Compensation

Key management includes the Company's directors, officers and any employees with authority and responsibility for planning, directing and controlling the activities of an entity, directly or indirectly.

For the six months ended January 31, 2017, the Company incurred professional fees of $47,300 (2016 - $36,000) from Branson Corporate Services, a company in which a company with a related director has a 49% interest.

For the six months ended January 31, 2017, the Company incurred consulting fees of $96,000 (2016 - $96,000) from FMI Capital Advisory Inc., a company with a related director.

For the six months ended January 31, 2017, the Company incurred professional fees of $126,383 (2016 - $16,089) from Fogler Rubinoff, LLP, a law firm in which a director of the company is a partner.

Total key management compensation paid to the management and directors amounted to $145,136 (2016 - $137,713) for the six months ended January 31, 2017. In addition, 2,250,000 stock options were issued to directors and officers during the period.

As at January 31, 2017, $10,731 (2016 - $337,704) is included in accounts payable and accrued liabilities and $37,500 (2016 - $Nil) is included in shares to be issued.

For the six months ended January 31, 2017, the Company incurred interest of $3,228 (2016 - $13,909) under the subordinate convertible debenture.

Disclosure of outstanding share data

As at January 31, 2017, the Company had 242,906,121 Common Shares outstanding, 10,492,500 options of which 8,592,500 are exercisable and warrants outstanding of 43,082,820. Accordingly, as at January 31, 2017, the Company has fully diluted share capital of 296,481,441 shares.

As at the date of this MD&A, the Company had 248,637,877 Common Shares outstanding, 11,442,500 options exercisable at a weighted average price of $0.12 per share expiring between October 14, 2018 and October 17, 2021, and 37,613,464 warrants outstanding exercisable at a weighted average price of $0.14 between June 2, 2017 and November 24, 2018. Accordingly, as at the date of this MD&A, the Company has fully diluted share capital of 248,637,877 shares.

Subsequent events

- Subsequent to January 31, 2017, the Company incorporated the following US subsidiaries: NH (Oregon) Properties LLC, NH (Pennsylvania) LLC, Growco Nevada Inc., NH Nevada LLC, NH Operations LLC, NH Processing (Nevada) Inc., and NH Properties (Nevada) LLC. On February 8, 2017, 850,000 options were granted to a consultant as part of service fee. The options are exercisable into common shares of the Company at a price of $0.205 per Common share for a period of two years from the date of issuance.

- On February 16, 2017, 500,000 options were granted to a consulting company as part of service fee. The options are exercisable into common shares of the Company at a price of $0.20 per Common share for a period of two years from the date of issuance.

- On February 17, 2017, the Company placed an additional US$900,000 in escrow in relation to the acquisition of provisional producer and processor licenses ("Henderson licenses") in Henderson, Nevada (Note 19) and advanced a refundable deposit of US$160,000 to acquire a real estate property to which the Henderson licenses are attached to (Note 7).

whereby Lakeside will build medical and adult use cannabis cultivation facilities ("Proposed Transaction").

As a part of the Proposed Transaction, Lakeside will enter into the following arrangements with the Company:

(i) Nutritional High will assign to Lakeside its right to acquire a Provisional Marijuana Cultivation License issued by the Nevada Division of Public and Behavioral Health (the "Nevada Cultivation License") for a cash payment of US$500,000; and

(ii) Lakeside will form a joint venture company with Nutritional High for the purposes of acquiring and holding a real property located in Henderson, Nevada ("Henderson Property") to be licensed for the operation of a medical marijuana cultivation facility (the "Nevada JV");

(iii) Nutritional High will lease to Lakeside land and a building in Pueblo, Colorado ("Pueblo Facility") which qualify for marijuana cultivation. Lakeside will sublease the Pueblo Facility to Palo Verde, LLC ("Palo Verde"), a party which has applied to renew a Cultivation License in Colorado respecting the Pueblo Facility.

The Company is under the contract to purchase the Nevada Cultivation License, from a third party ("Vendor") located in Nevada for US$500,000. The Vendor acquired the Nevada Cultivation License it in a competitive process and has not yet generated revenue.

- On February 28, 2017, the revolving loan to Palo Verde LLC was extended to May 31, 2018 ("Maturity Date") and the revolving loan commitment was increased from US$150,000 to US$375,000. In addition, the interest on the revolving loan will accrue until Maturity Date and a 1% renewal fee shall be added to the principal amount as a consideration for extending the loan.

- In March 2017, the Company entered into an agreement to purchase a real estate property and advanced US$100,000 as deposit.

- In March 2017, the Company entered into an agreement to purchase a real estate property and advanced US$20,000 as a deposit.

- On March 17, the Company sold the Lawrenceville property back to its original vendors by paying a consideration of $80,000, of which 50% was covered by ILDISP, in lieu of forgiving the outstanding seller take-back mortgage.

- On March 24, 2017, the Company closed an acquisition of a real estate property in The City of La Pine located in Deschutes County, Oregon for US$399,000.

**Off-Balance Sheet Arrangements**

As of January 31, 2017, the Company has no off-balance sheet arrangements.

**Critical Accounting Estimates and judgments**

The preparation of these condensed interim consolidated financial statements requires management to make judgments and estimates and form assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, management evaluates its judgments and estimates in relation to assets, liabilities, revenue and expenses. Management uses historical experience and various other factors it believes to be reasonable under the given circumstances as the basis for its judgments and estimates. Actual outcomes may differ from these estimates under different assumptions and conditions. The most significant estimates relate to recoverability of loan receivable and rent receivable, valuation of deferred income tax amounts, gain on de-consolidation of NHMDI and SMHI and valuation of warrants and shares issued during private placements and measurement of derivative liability.
The most significant judgments relate to recognition of deferred tax assets and liabilities, assessment of functional currency, share-based payments, warrants, determination of derivative liability of convertible debt, loss of control of NHMDI and SMHI and determination of the joint arrangement as a joint operation or joint venture.

**Significant accounting policies**

**Share based payments**

**Share based payment transactions**

Employees (including directors and senior executives) of the Company receive a portion of their remuneration in the form of share-based payments, whereby employees render services as consideration for equity instruments ("equity-settled transactions").

In situations where equity instruments are issued and some or all of the goods or services received by the entity as consideration cannot be specifically identified, they are measured at fair value of the share-based payment.

**Equity settled transactions**

The costs of equity-settled transactions with employees are measured by reference to the fair value of the equity instruments at the date on which they are granted.

The costs of equity-settled transactions are recognized, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled, ending on the date on which the relevant employees become fully entitled to the award ("the vesting date"). The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the Company's best estimate of the number of equity instruments that will ultimately vest. The profit or loss charge or credit for a period represents the movement in cumulative expense recognized as at the beginning and end of that period and the corresponding amount is represented in share option reserve.

No expense is recognized for awards that do not ultimately vest.

**Loss per share**

Basic loss per share is computed by dividing the net loss available to common shareholders by the weighted average number of Common Shares outstanding during the period. The computation of diluted loss per share assumes conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on loss per share. When there is a loss, no potential shares are included in the computation as they are anti-dilutive.

**Financial assets**

All financial assets are initially recorded at fair value and designated upon inception into one of the following four categories: held to maturity, available for sale, loans and receivables, or at fair value through profit or loss ("FVTPL").

Financial assets classified as FVTPL are measured at fair value with realized gains and losses recognized through earnings. The Company's cash and cash equivalents are classified as FVTPL.

Financial assets classified as loans and receivables and held to maturity are measured at amortized cost. The Company classified loans and other receivables as loans and receivables.
Financial assets classified as available for sale are measured at fair value with unrealized gains and losses recognized in other comprehensive income (loss) except for losses in value that are considered other than temporary. At July 31, 2016 and January 31, 2017, the Company has not classified any financial assets as available for sale or held to maturity.

Transaction costs associated with FVTPL financial assets are expensed as incurred, while transaction costs associated with all other financial assets are included in the initial carrying amount of the asset.

**Financial liabilities**

All financial liabilities are initially recorded at fair value and designated upon inception as FVTPL or other financial liabilities.

Financial liabilities classified as other financial liabilities are initially recognized at fair value less directly attributable transaction costs. After initial recognition, other financial liabilities are subsequently measured at amortized cost using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments through the expected life of the financial liability, or, where appropriate, a shorter period. The Company's accounts payable and accrued liabilities are classified as other financial liabilities.

Financial liabilities classified as FVTPL include financial liabilities held for trading and financial liabilities designated upon initial recognition as FVTPL. Derivatives, including separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments. Fair value changes on financial liabilities classified as FVTPL are recognized through the statement of comprehensive income. At July 31, 2016 and January 31, 2017, the Company had not classified any financial liabilities as FVTPL.

**Cash**

Cash in the statement of financial position is comprised of cash in bank and held in Company’s lawyers trust account.

**Related party transactions**

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control or common significant influence, related parties may be individuals or corporate entities. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

**Credit Risk**

Credit risk is the risk of loss associated with counterparty's inability to fulfill its payment obligations. The Company's credit risk is primarily attributable to cash, accounts receivable and amounts due from Palo Verde LLC including rental income receivable (Note 5). Collection of the amounts due from Palo Verde LLC is contingent on the success of Palo Verde LLC’s operation, which have not yet commenced in full-fledged. The Company has no significant concentration of credit risk arising from operations. Cash is held with a reputable Canadian credit union which is closely monitored by management. Accounts receivable consists mostly of harmonized sales tax due from the Canadian government. The Board of Directors meets on a quarterly basis to review and assess the risk profile of the loan. Management believes that the credit risk concentration with respect to financial instruments included in cash and other receivable is not material for the Company. Management has considered the credit risk concentration with respect to amounts due from Palo Verde LLC, and has provisioned for the balance accordingly.
Liquidity Risk

Liquidity risk is the risk that the Company will not have sufficient cash resources to meet its financial obligations as they come due. The Company’s liquidity and operating results may be adversely affected if the Company’s access to the capital market is hindered, whether as a result of a downturn in stock market conditions generally or related to matters specific to the Company. The Company generates cash flow primarily from its financing activities. The Company’s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at January 31, 2017, the Company had current assets of $6,135,506 (2016 - $299,115) and current liabilities of $1,179,752 (2016 - $1,731,657). All of the Company’s financial liabilities and receivables, excluding Amounts due from Palo Verde LLC (Note 5), have contractual maturities of less than 90 days and are subject to normal trade terms. As at January 31, 2017, working capital of the Company is $4,955,754 (2016 – deficiency of $1,432,542).

Foreign currency exchange risk

The Company conducts a portion of its purchases in US dollars which results in the foreign currency exchange risk. The Company does not consider its exposure to foreign currency exchange risk to be material. An increase (decrease) of 10% in the currency exchange rate of the Canadian dollar versus US dollar would have impacted net loss by $8,196 (2016 - $26,958) as a result of the Company’s exposure to currency exchange rate fluctuations.

Interest rate risk

Interest rate risk is the potential for financial loss arising from changes in interest rates. Financial instruments that potentially subject the Company to interest rate risk include financial liabilities with fixed interest rates. The Company manages interest rate risk by monitoring market conditions and the impact of interest rate fluctuations on its debt.

Net earnings are sensitive to the impact of a change in interest rates on the average balance of interest bearing financial liabilities during the year.

Risk Factors

There are numerous and various risks, known and unknown, that may prevent the Company from achieving its goals. It is believed that these are the factors that could adversely affect the Company’s business, financial condition or results of operation. In such case, the trading price of the Common Shares could decline and investors could lose all or part of their investment. The following is a summary of certain risks that could be applicable to the business of the Company:

Limited Operating History

The Company has a very limited history of operations, is in the early stage of development and must be considered a start-up. As such, the Company is subject to many risks common to such enterprises, including under-capitalization, cash shortages, limitations with respect to personnel, financial and other resources and lack of revenues. There is no assurance that the Company will be successful in achieving a return on shareholders’ investment and the likelihood of success must be considered in light of its early stage of operations. The Company has no history of earnings. Because the Company has a limited operating history in emerging area of business, you should consider and evaluate its operating prospects in light of the risks and uncertainties frequently encountered by early-stage companies in rapidly evolving markets. These risks may include:

- risks that it may not have sufficient capital to achieve its growth strategy;
- risks that it may not develop its product and service offerings in a manner that enables it to be profitable and meet its customers' requirements;
- risks that its growth strategy may not be successful;
- risks that fluctuations in its operating results will be significant relative to its revenues; and
The Company’s future growth will depend substantially on its ability to address these and the other risks described in this section. If it does not successfully address these risks, its business may be significantly harmed.

Reliance on Securing Agreements with Licenses Producers

The regulatory framework in most States restricts the Company from obtaining a License to grow, store and sell marijuana products. As such, the Company relies on securing agreements with Licenses Producers in the targeted jurisdictions that have been able to obtain a License with the appropriate regulatory authorities. Failure of a Licenses Producer to comply with the requirements of their License or any failure to maintain their License would have a material adverse impact on the business, financial condition and operating results of the Company. Should the regulatory authorities not grant a License or grant a License on different terms unfavorable to the Licensed Operators, and should the Company be unable to secure alternative Licensed Operators, the business, financial condition and results of the operation of the Company would be materially adversely affected.

If the federal government changes its approach to the enforcement of laws relating to marijuana, the Company would need to seek to replace those tenants with non-marijuana tenants, who would likely pay lower rents. It is likely that the Company would realize an economic loss on its capital acquisitions and improvements made to its capital assets specific to the marijuana industry, and the Company would likely lose all or substantially all of its investments in the markets affected by such regulatory changes.

The Company will advance significant funds to Palo Verde in a form of unsecured loans, which the Company may not be able to collect if Palo Verde fails to achieve commercial production. Palo Verde is a development stage entity with limited capacity to raise funds. There is no assurance that any or all of the amounts loaned will be recovered by the Company. If Palo Verde is unable to commence commercial production in a profitable fashion or secure an alternative source of funds, the full amount of the loan might be written off.

Regulation

The activities of the Company are subject to regulation by governmental authorities. Achievement of the Company's business objectives are contingent, in part, upon compliance with regulatory requirements enacted by these governmental authorities and obtaining all regulatory approvals, where necessary, for the sale of its products. The Company cannot predict the time required to secure all appropriate regulatory approvals for its products, or the extent of testing and documentation that may be required by governmental authorities. Any delays in obtaining, or failure to obtain regulatory approvals would significantly delay the development of markets and products and could have a material adverse effect on the business, results of operations and financial condition of the Company.

The Company's operations are subject to a variety of laws, regulations and guidelines relating to the manufacture, management, transportation, storage and disposal of marijuana but also including laws and regulations relating to health and safety, the conduct of operations and the protection of the environment. The Company is currently in compliance with all such laws. Changes to such laws, regulations and guidelines due to matters beyond the control of the Company may cause adverse effects to the Company's operations.

Local, state and federal laws and regulations governing marijuana for medicinal and recreational purposes are broad in scope and are subject to evolving interpretations, which could require the Company to incur substantial costs associated with bringing the Company's operations into compliance. In addition, violations of these laws, or allegations of such violations, could disrupt the Company's operations and result in a material adverse effect on its financial performance. It is beyond the Company's scope to predict the nature of any future change to the existing laws, regulations, policies, interpretations or applications, nor can the Company determine what effect such changes, when and if promulgated, could have on the Company's business.
Our business operation is dependent on state laws pertaining to the marijuana industry. Continued development of the marijuana industry is dependent upon continued legislative authorization of marijuana at the state level. Any number of factors could slow or halt progress in this area. Further, progress, while encouraging, is not assured. While there may be ample public support for legislative action, numerous factors impact the legislative process. Any one of these factors could slow or halt use of marijuana, which would negatively impact our proposed business.

The concepts of "medical marijuana and "retail marijuana" do not exist under U.S. federal law. The Federal Controlled Substances Act classifies "marihuana" as a Schedule I drug. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. As such, marijuana-related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of marijuana are illegal under U.S. federal law. Strict compliance with state laws with respect to marijuana will neither absolve the Company of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company.

As of December 29, 2016, 28 states, the District of Columbia and Guam allow their residents to use medical marijuana. Voters in the states of Colorado, Washington, Oregon, Alaska, California, Nevada, Massachusetts, and Maine have approved and have implemented or are implementing regulations to legalize cannabis for adult use. The state laws are in conflict with the Federal Controlled Substances Act, which makes marijuana use and possession illegal on a national level. The Obama administration has made numerous statements indicating that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws allowing the use and distribution of medical marijuana. However, there is no guarantee that the new Trump administration will not change the government’s stated policy regarding the low-priority enforcement of federal laws. Any such change in the federal government’s enforcement of current federal laws could cause significant financial damage to the Company and its stockholders, including the potential exposure to criminal liability.

The constant evolution of laws and regulations affecting the marijuana industry could detrimentally affect our operations. Local, state and federal medical marijuana laws and regulations are broad in scope and subject to changing interpretations. These changes may require us to incur substantial costs associated with legal and compliance fees and ultimately require us to alter our business plan. Furthermore, violations of these laws, or alleged violations, could disrupt our business and result in a material adverse effect on our operations. In addition, we cannot predict the nature of any future laws, regulations, interpretations or applications, and it is possible that regulations may be enacted in the future that will be directly applicable to our business.

**Local Regulation could change and negatively impact on the Company's operations**

Most US states that permit marijuana for adult use or medical use provide local municipalities with the authority to prevent the establishment of medical or adult use marijuana businesses in their jurisdictions. If local municipalities where the Company or its Licensed Operators have established facilities decides to prohibit marijuana businesses from operating, the Company or its Licensed Operators could be forced to relocate operations at great cost to the Company, and the Company or its Licensed Operators may have to cease operations in such state entirely if alternative facilities cannot be secured.

**Regulation that may hinder the Company's Ability to Establish and Maintain Bank Accounts**

The U.S. federal prohibitions on the sale of marijuana may result in Licensed Operators being restricted from accessing the U.S. banking system and they may be unable to deposit funds in federally insured and licensed banking institutions. While the Company does not anticipate dealing with banking restrictions directly relating to its business, banking restrictions could nevertheless be imposed due to the Company's banking institutions not accepting payments from Licensed Operators. Licensed Operators at times do not have deposit services and are at risk that any bank accounts they have could be closed at any time. Such risks increase costs to the Company and Licensed Operators. Additionally, similar risks are associated with large amounts of cash at these businesses. These businesses require heavy security with respect to holding and transport of cash, whether or not they have bank accounts.
In the event financial service providers do not accept accounts or transactions related to the marijuana industry, it is possible that Licensed Operators may seek alternative payment solutions, including but not limited to crypto currencies such as Bitcoin. There are risks inherent in crypto currencies, most notably its volatility and security issues. If the industry was to move towards alternative payment solutions and accept payments in crypto currency the Company would have to adopt policies and protocols to manage its volatility and exchange rate risk exposures. The Company's inability to manage such risks may adversely affect the Company's operations and financial performance.

**Product Liability, Operational Risk**

As a licensing company (in the case of the Company) and a manufacturer and distributor of products (in the case of the Licensed Operators) designed to be ingested by humans, the Licensed Operators and the Company face an inherent risk of exposure to product liability claims, regulatory action and litigation if its products are alleged to have caused significant loss or injury. In addition, the manufacture and sale of marijuana-infused products based on the Company's recipes and brands involve the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Previously unknown adverse reactions resulting from human consumption of the Company's and the Licensed Operator's products alone or in combination with other medications or substances could occur.

**Product Recalls**

Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labeling disclosure. If any of the products developed by the Company and sold by Licensed Operators are recalled due to an alleged product defect or for any other reason, the Company could be required to incur the unexpected expense relating to the recall and any legal proceedings that might arise in connection with the recall. In addition, a product recall may require significant management attention and could harm the image of the brand and Company.

**Uninsurable Risks**

The medical and retail marijuana business is subject to several risks that could result in damage to or destruction of properties or facilities or cause personal injury or death, environmental damage, delays in production and monetary losses and possible legal liability. It is not always possible to fully insure against such risks, and the Company may decide not to take out insurance against such risks as a result of high premiums or other reasons. Should such liabilities arise, they could reduce or eliminate any future profitability and result in increasing costs and a decline in the value of the securities of the Company. The Company does not currently have any insurance policies covering its properties or the operation of its business and any liabilities that may arise as a result any of the above noted risks may cause a material adverse effect on the financial condition of the Company.

**Additional Financing**

The Company may need to raise significant additional funds in order to support its growth, develop new or enhanced services and products, respond to competitive pressures, acquire or invest in complementary or competitive businesses or technologies, or take advantage of unanticipated opportunities. If its financial resources are insufficient, it will require additional financing in order to meet its plans for expansion. The Company cannot be sure that this additional financing, if needed, will be available on acceptable terms, or at all.

Furthermore, any debt financing, if available, may involve restrictive covenants, which may limit its operating flexibility with respect to business matters. If additional funds are raised through the issuance of equity securities, the percentage ownership of existing shareholders will be reduced, such shareholders may experience additional dilution in net book value, and such equity securities may have rights, preferences or privileges senior to those of its existing shareholders.

Access to public and private capital and financing continues to be negatively impacted by many factors as a result of the global financial crisis and global recession. Such factors may impact the Company's ability to obtain debt and equity financing in the future on favorable terms or obtain any financing at all. Additionally, global economic conditions may cause a long term decrease in asset values. If such global volatility, market turmoil and the global recession continue, the Company's operations and financial condition could be adversely impacted.
Risks Affecting the Real Estate Industry

The Company is subject to risks generally associated with ownership of real estate, including: (a) changes in general economic or local conditions; (b) changes in supply of, or demand for, similar or competing properties in the area; (c) bankruptcies, financial difficulties or defaults by tenants or other parties (including Licensed Operators and Licensed Operators); (d) increases in operating costs, such as taxes and insurance; (e) the inability to achieve full stabilized occupancy at rental rates adequate to produce targeted returns; (f) periods of high interest rates and tight money supply; (g) excess supply of rental properties in the market area; (h) liability for uninsured losses resulting from natural disasters or other perils; (i) liability for environmental hazards; and (j) changes in tax, real estate, environmental, zoning or other laws or regulations. There is no assurance that the Company's investments will yield an economic profit.

Weakness in regional and national economies could materially and adversely impact the Licensed Operators and Licensed Operators leasing the real estate properties that the Company's may acquire in the future. If the Licensed Operators or Licensed Operators suffer a business disruption or the Company's ability to collect the rents from those parties may be limited, and the recourse available to the Company can be limited. As such, this may hinder the Company's ability to service its financial obligations, and in some cases may lead to complete loss of the Company's assets if its lenders were to foreclose.

Taxes

U.S. federal prohibitions on the sale of marijuana may result in the Company not being able to deduct certain costs from its revenue for U.S. federal taxation purposes if the U.S. Internal Revenue Service determines that revenue sources of the Company are generated from activities which are not permitted under U.S. federal law.

Illegal Drug Dealer Could Pose Threats

Currently, there are many drug dealers and cartels that cultivate, buy, sell and trade marijuana in the United States, Canada and worldwide. Many of these dealers and cartels are violent and dangerous, well financed and well organized. It is possible that these dealers and cartels could feel threatened by legalized marijuana businesses such as those with whom the Company does business and could take action against or threaten the Company, its principals, employees and/or agents and this could negatively impact the Company and its business.

Reliance on Management

The success of the Company is currently dependent on the performance of its senior management. The loss of the services of these persons would have a material adverse effect on the Company's business and prospects in the short term. There is no assurance the Company can maintain the services of its officers or other qualified personnel required to operate its business. Failure to do so could have a material adverse effect on the Company and its prospects.

Factors which may Prevent Realization of Growth Targets

The Company is currently in the early development stage. There is a risk that the additional resources will be needed and milestones will not be achieved on time, on budget, or at all, as they can be adversely affected by a variety of factors, including some that are discussed elsewhere in these risk factors and the following as it relates to the Company and its Licensed Operators:

- delays in obtaining, or conditions imposed by, regulatory approvals;
- facility design errors;
- environmental pollution;
- non-performance by third party contractors;
- increases in materials or labour costs;
- construction performance falling below expected levels of output or efficiency;
- breakdown, aging or failure of equipment or processes;
- contractor or operator errors;
- labour disputes, disruptions or declines in productivity;
• inability to attract sufficient numbers of qualified workers;
• disruption in the supply of energy and utilities; and
• major incidents and/or catastrophic events such as fires, explosions, earthquakes or storms.

*Risks Associated with Increasing Competition*

The marijuana industry is highly competitive. The Company will compete with numerous other businesses in the medicinal and recreational industry, many of which possess greater financial and marketing resources and other resources than the Company. The marijuana business is often affected by changes in consumer tastes and discretionary spending patterns, national and regional economic conditions, demographic trends, consumer confidence in the economy, traffic patterns, local competitive factors, cost and availability of raw material and labour, and governmental regulations. Any change in these factors could materially and adversely affect the Company's operations.

The Company expects to face additional competition from new entrants. If the number of legal users of marijuana in its target jurisdiction increases, the demand for products will increase and the Company expects that competition will become more intense, as current and future competitors begin to offer an increasing number of diversified products.

*The Products Provided by the Company to Licensed Operators May Become Subject to Regulation Governing Food and Related Products*

Should the Federal government legalize marijuana for medical or recreational use nation-wide, it is possible that the U.S. Food and Drug Administration ("FDA") would seek to regulate the products under the Food, Drug and Cosmetics Act of 1938. The FDA may issue rules and regulations including certified good manufacturing practices related to the growth, cultivation, harvesting and processing of medical marijuana and marijuana-infused products. Clinical trials may be needed to verify efficacy and safety of the medical marijuana. It is also possible that the FDA would require that facilities where medical marijuana is cultivated be registered with the applicable government agencies and comply with certain federal regulations. In the event any of these regulations are imposed, The Company cannot foresee the impact on its operations and economics. If the Company or the Licensed Operators are unable to comply with the regulations and or registration as prescribed by the FDA or another federal agency, the Company or the Royalty Producer may be unable to continue to operate in its current form or at all.

*Environmental and Employee Health and Safety Regulations*

The Company's operations are subject to environmental and safety laws and regulations concerning, among other things, emissions and discharges to water, air and land, the handling and disposal of hazardous and non-hazardous materials and wastes, and employee health and safety. The Company will incur ongoing costs and obligations related to compliance with environmental and employee health and safety matters. Failure to comply with environmental and safety laws and regulations may result in additional costs for corrective measures, penalties or in restrictions on our manufacturing operations. In addition, changes in environmental, employee health and safety or other laws, more vigorous enforcement thereof or other unanticipated events could require extensive changes to the Company's operations or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of the Company.

*Difficult to Forecast*

The Company must rely largely on its own market research to forecast sales as detailed forecasts are not generally obtainable from other sources at this early stage of the marijuana industry in Canada and the U.S. A failure in the demand for its products to materialize as a result of competition, technological change, market acceptance or other factors could have a material adverse effect on the business, results of operations and financial condition of the Company.

*Holding Company*

As a holding company with no material assets other than the stock of the Company's operating subsidiaries and intellectual property, nearly all of the Company's funds generated from operations are generated by the Company's
operating subsidiaries. The Company's subsidiaries are subject to requirements of various regulatory bodies, both domestically and internationally. Accordingly, if the Company's operating subsidiaries are unable, due to regulatory restrictions or otherwise, to pay the Company's dividends and make other payments to the Company when needed, the Company may be unable to satisfy the Company's obligations when they arise.

Management of Growth

The Company may be subject to growth-related risks including capacity constraints and pressure on its internal systems and controls. The ability of the Company to manage growth effectively will require it to continue to implement and improve its operational and financial systems and to expand, train and manage its employee base. The inability of the Company to deal with this growth may have a material adverse effect on the Company's business, financial condition, results of operations and prospects.

Dividends

The Company has no earnings or dividend record, and does not anticipate paying any dividends on the Common Shares in the foreseeable future. Dividends paid by the Company would be subject to tax and, potentially, withholdings.

Currency Exchange Rates

Exchange rate fluctuations may adversely affect the Company's financial position and results. It is anticipated that a significant portion of the Company's business will be conducted in the United States using U.S. dollars. The Company's financial results are reported in Canadian Dollars and costs are incurred primarily in U.S. dollars in its Marijuana–Infused Products Segment. The depreciation of the Canadian Dollar against the U.S. Dollar could increase the actual capital and operating costs of the Company's U.S. operations and materially adversely affect the results presented in the Company's financial statements.

Officers and Directors of the Company Own Significant Shares and Can Exercise Significant Influence

The officers and directors of the Company, as a group, own a substantial number of the outstanding common shares (on a fully diluted basis). As such, as shareholders, the officers and directors will be able to exert significant influence on matters requiring approval by shareholders, including the election of directors and the approval of any significant corporate transactions. The concentration of ownership may also have the effect of delaying, deterring or preventing a change in control and may make some transactions more difficult or impossible to complete without the support of these shareholders.

We share control in joint venture projects, which limits our ability to manage third-party risks associated with these projects.

Joint ventures often have shared control over the operation of our joint venture assets, such as the joint-venture arrangement with Illinois investor group, and do not control all the decisions of the joint ventures. Therefore, joint venture investments may involve risks such as the possibility that a co-venture in an investment might become bankrupt, be unable to meet its capital contribution obligations, have economic or business interests or goals that are inconsistent with our business interests or goals, or take actions that are contrary to our instructions or to applicable laws and regulations. In addition, we may be unable to take action without the approval of our joint venture partners, or our joint venture partners could take actions binding on the joint venture without our consent. Consequently, actions by a co-venture or other third-party could expose us to claims for damages, financial penalties and reputational harm, any of which could have an adverse effect on our business and operations. In addition, we may agree to guarantee indebtedness incurred by a joint venture or co-venture or provide standard indemnifications to lenders for loss liability or damage occurring as a result of our actions or actions of the joint venture or other co-ventures. Such a guarantee or indemnity may be on a joint and several basis with a co-venture, in which case we may be liable in the event such co-
venture defaults on its guarantee obligation. The non-performance of such obligations may cause losses to us in excess of the capital we initially may have invested or committed under such obligations.

Preparing our financial statements requires us to have access to information regarding the results of operations, financial position and cash flows of our joint ventures. Any deficiencies in our joint ventures’ internal controls over financial reporting may affect our ability to report our financial results accurately or prevent or detect fraud. Such deficiencies also could result in restatements of, or other adjustments to, our previously reported or announced operating results, which could diminish investor confidence and reduce the market price for our shares. Additionally, if our joint ventures are unable to provide this information for any meaningful period or fail to meet expected deadlines, we may be unable to satisfy our financial reporting obligations or timely file our periodic reports.

Although our joint ventures may generate positive cash flow, in some cases they may be unable to distribute that cash to the joint venture partners. Additionally, in some cases our joint venture partners control distributions and may choose to leave capital in the joint venture rather than distribute it. Because our ability to generate liquidity from our joint ventures depends in part on their ability to distribute capital to us, our failure to receive distributions from our joint venture partners could reduce our return on these investments.

The joint venture might require a need for additional capital infusions which might create an obligation on the Company to make additional contributions, failing to do which may result in reduction of the Company's interest in NHMDI and SMHI. In addition, Illinois investor group's failure to contribute may create an greater need for the Company to contribute additional capital, which may not be available to the Company on favorable terms or at all.

Non-compliance with federal, provincial or state laws and regulations, or the expansion of current, or the enactment of new laws or regulations, could adversely affect the Company's Business.

The activities of the Company are subject to regulation by governmental authorities. Achievement of the Company's Business objectives are contingent, in part, upon compliance with regulatory requirements enacted by these governmental authorities and obtaining all regulatory approvals, where necessary, for the sale of its products. The Company cannot predict the time required to secure all appropriate regulatory approvals for its products, or the extent of testing and documentation that may be required by governmental authorities. Any delays in obtaining, or failure to obtain regulatory approvals would significantly delay the development of markets and products and could have a material adverse effect on the Business, results of operations and financial condition of the Company.

While cannabidiol ("CBD") can be found in certain strains of cannabis, which faces significant restrictions on use and distribution under the United States Controlled Substances Act ("CSA"), the Company is not sourcing CBD from cannabis at present.

While oil derived from industrial hemp stalk that has naturally occurring THC content equal to or less than 0.3% is excluded from the definition of marijuana under the CSA, there is no certainty that this exclusion could not be altered by court or governmental action or re-interpretation. There is no certainty that the United States Food and Drug Administration ("FDA") will not regulate the use of hemp oil as a drug and prohibit use as a dietary ingredient. There is no certainty that hemp oil will be considered a grandfathered dietary ingredient under the Dietary Supplement Health and Education Act of 1994 ("DSHEA"), or would otherwise be permitted for use under the DSHEA. The FDA has taken steps to pursue companies that manufacture hemp-infused products that make health and medical claims about their products, and may take steps to pursue companies that manufacture marijuana products. This may include Licensed Operators, which would adversely effect the Company's financial performance.

The Company relies on the supply of hemp stalk oil extracts, which is imported into the United States from other countries, as the United States Drug Enforcement Administration ("DEA") has taken a position that CBD is a marijuana derivative and, therefore, a Schedule I drug. Currently, the definition of "marijuana" in the CSA does not include the plant's "mature stalks", which are used to create hemp (which only contains trace amounts of THC and has no psychoactive effect). Hemp stalk oil is not scheduled under the CSA and therefore, is also not under the enforcement authority of the DEA. Currently, the DEA does not take jurisdiction over hemp stalk oil products, but controls hemp
cultivation, and companies that wish to cultivate hemp in the United States must apply for a permit with the DEA. If in future DEA takes jurisdiction to regulate hemp stalk oil products, the Company may become subject to additional licensing requirements, which may require additional capital. There is no assurance that the Company will be able to obtain any such licenses, or be eligible to apply for such licenses, which would adversely affect the Company's Business.

Internal Control over Financial Reporting

Internal controls over financial reporting are procedures designed to provide reasonable assurance that transactions are properly authorized, assets are safeguarded against unauthorized or improper use, and transactions are properly recorded and reported. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance with respect to the reliability of financial reporting and financial statement preparation.

During the six months ended January 31, 2017, there were no changes in the Company's internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are designed to provide reasonable assurance that all relevant information is gathered and reported to senior management, including the Company's President and Chief Executive Officer and Chief Financial Officer, on a timely basis so that appropriate decisions can be made regarding public disclosure. As at January 31, 2017 covered by this management's discussion and analysis, management of the Company, with the participation of the President and Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of the Company's disclosure controls and procedures as required by Canadian securities laws. Based on that evaluation, the President and Chief Executive Officer and the Chief Financial Officer have concluded that, as of the end of the period covered by this management's discussion and analysis, the disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in the Company's annual filings and interim filings (as such terms are defined under Multilateral Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings) and other reports filed or submitted under Canadian securities laws is recorded, processed, summarized and reported within the time periods specified by those laws and that material information is accumulated and communicated to management of the Company, including the President and Chief Executive Officer and the Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Cautionary Note Regarding Forward Looking Statements

This Management's Discussion and Analysis includes "forward-looking statements", within the meaning of applicable securities legislation, which are based on the opinions and estimates of Management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "budget", "plan", "continue", "estimate", "expect", "forecast", "may", "will", "project", "predict", "potential", "targeting", "intend", "could", "might", "should", "believe" and similar words suggesting future outcomes or statements regarding an outlook. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include, without limitation: the intention to complete the listing; the description of the Company that assumes completion of the listing of its Common Shares; the intention to grow the business and operations of the Company; anticipated timing for the ability of the Company to agree to terms of royalty agreements with Licensed Operators; expected growth in the number of users of Medical Marijuana in Canada; the risk of foreign exchange rate fluctuations, the ability of the Company to fund the capital and operating expenses necessary to achieve its business objectives, the uncertainty associated with commercial negotiations and risks associated with international business activities, as well as those risks described in public disclosure documents filed by the Company. Due to the risks, uncertainties and assumptions inherent in forward-looking statements,
prospective investors in securities of the Company should not place undue reliance on these forward-looking statements.

Readers are cautioned that the foregoing lists of risks, uncertainties and other factors are not exhaustive. The forward-looking statements contained herein are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or in any other documents filed with Canadian securities regulatory authorities, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.

Management's Responsibility for Financial Information

Management is responsible for all information contained in this report. The condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards and include amounts based on management's informed judgments and estimates. The financial and operating information included in this report is consistent with that contained in the condensed interim consolidated financial statements for the six months ended January 31, 2017 and the audited consolidated financial statements for the year ended July 31, 2016 in all material aspects.

Management maintains internal controls to provide reasonable assurance that financial information is reliable and accurate and assets are safeguarded.

The Audit Committee has reviewed the condensed interim consolidated financial statements with management. The Board of Directors has approved the condensed interim consolidated financial statements on the recommendation of the Audit Committee.

March 31, 2017

Jim Frazier
Chief Executive Officer